was established in April 2002 as the company's late-stage research unit, with state-of-the-art laboratory facilities at the Innovation Centre
in Allschwil, Basel, Switzerland.The strategic rationale for this investment is to increase the company's ability to identify and produce attractive candidate compounds for development and to create in-house intellectual property which complements the portfolio of in-licensed compounds.Experimenta
commenced operations in 2002 with 10 employees and this has quickly grown to about 50 scientists and technicians in 2007.There has been a corresponding increase in physical laboratory space from 800 to 1400 square meters, together with significant investment in technical equipment.
In April 2003 Experimenta
established a research collaboration with an American company, Locus Pharmaceuticals Inc.
, to design novel renin inhibitors that are a new class of therapy for cardiovascular diseases.This collaboration combines the computational technology of Locus
with the chemical lead optimisation expertise of Experimenta
During 2003 and 2004 Experimenta
has added four new technical disciplines to significantly expand its in-house capabilities.The rationale for this development is to ensure that Experimenta
reduces the traditional time period taken from first synthesis of a compound to entry into man in a cost-efficient manner, and that it creates broader intellectual property rights and captures more value for the company.
is today working on multiple series of novel renin inhibitors.It has already produced excellent results in animal models with the SPP600 and SPP1100 series for lowering blood pressure and improving renal protection.The unit now has the capacity to develop compounds with other modes of action for cardiovascular and metabolic diseases.Speedel
is committed to the development of this strategic investment as a platform for the company's continued success.Speedel share price SPPN CHF131.00 Speedel bond price SPP07 CHF112.95 01 October SPEEDEL DISCLOSES CHANGES IN SIGNIFICANT SHAREHOLDERS 15 August SPEEDEL SHAREHOLDERS ELECT FOUR NOVARTIS OFFICERS AS NEW MEMBERS TO THE BOARD OF DIRECTORS 12 August SPEEDEL ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2008 06 August SPEEDEL ANNOUNCES NEW DATE FOR Q2 2008 FINANCIAL REPORTING